1. Home
  2. /
  3. Projects
  4. /
  5. Page 3

research

Acceptability of and confidence in novel tuberculosis vaccines among adults living with HIV

Objective: Several novel tuberculosis vaccines (NTVs) are being evaluated in clinical trials. Understanding the perception of acceptability and confidence in NTVs will inform implementation strategies. Conclusion: NTV acceptability was high amongst these PWH, and they preferred community-based delivery models. Our findings may inform strategies to increase implementation of NTVs among PWH in South Africa.

A model for the epidemiological impact of tuberculosis policy options

Develops a new TB transmission model to help decision-makers comapre the epidemiological impact of different TB interventions and allocate resources. The model incorporates diagnosis, treatment, drug resistance, HIV status, age, and vaccination status, and was calibrated using data from 29 high burden countries. It demonstrates the potential impact of comprehensive TB interventions in Indonesia and Nigeria, including the possible use of a post-exposure TB vaccine

Community willingness towards a hypothetical new TB vaccine

Qualitative study exploring community willingness to accept a future TB vaccine in Nepal. It examines how knowledge, previous vaccination experiences, trust in health services, misinformation, perceived safety and effectiveness, costs, transportation, service delivery barriers and gender rleated actor influence willingness to receive a new TB vaccine

Prevention is better than cure’: a mixed methods study of communities’ and healthcare workers’ perspectives on new adult and adolescent TB vaccines and their implementation in Zambia

Mixed methods study examining community members' and healthcare workers' views on future TB vaccines for adults and adolescents in Zamibia. It assesses willingness to receive a TB vaccine, preferred vaccine characteristics, concerns about safety and efficacy, trusted information sources, barriers to uptake, and preferred approaches for vaccine delivery and implementation.

Facing up to reality? What to do if M72/AS01E doses are limited

The Ph3 trial for the vaccine candidate M72/AS01E is underway, and, assuming a positive result, could be licensed by 2030. Modelling suggested a large potential impact from introducing M72/AS01E but assumed an unconstrained dose supply. However, at least initially, it is likely that M72/AS01E will be supply-constrained. We estimated the effect of decisions surrounding the allocation of constrained doses on the potential global impact of M72/AS01E

Global impact and cost-effectiveness of tuberculosis interventions

The modelling study compares the population-level impact and cost-effectiveness of TB vaccination with other TB interventions. It models vaccination scale-up in Brazil, India, and South Africa and estimates that vaccination could prevent 15-28% of symptomatic TB episodes by 2050. It provides evidence to inform investment, policy, and planning for future TB vaccine introduction and scale-up.
Click to copy link of this header Menu